Jonathan D. Urban, Ph.D., DABT - ToxStrategies

Jonathan D. Urban, Ph.D., DABT
MANAGING SCIENTIST
ASSOCIATE PRACTICE DIRECTOR, HEALTH SCIENCES

CONTACT INFORMATION

ToxStrategies, Inc.
9390 Research Blvd, Suite 100
Austin, TX 78759
Phone (512) 351-7358
jurban@toxstrategies.com

PROFESSIONAL PROFILE

Dr. Jonathan Urban is a Managing Scientist and the Associate Director of the Health Sciences Practice with
ToxStrategies, Inc., in Austin, TX. Dr. Urban is a board-certified toxicologist with fifteen years’ experience studying
and evaluating the potential health effects of a wide range of environmental and occupational chemicals of
concern, food-related compounds, and consumer product ingredients and contaminants. He specializes in the use
of evidence-based methods in support of hazard and risk assessment and is involved in the firm’s integration of
these methods in the safety assessment development process. He has played an integral role in the firm’s efforts
to develop and apply comprehensive systematic review methods for chemical risk assessment, with experience in
all aspects of systematic review (problem formulation, PECO development, literature identification and screening,
use of critical appraisal tools for evaluating studies for risk of bias and external validity, as well as qualitative and
quantitative evidence integration). Dr. Urban has utilized this expertise in the development of critiques and
recommendations regarding health-based toxicity criteria for both state and federal regulatory agencies, industry,
and private-sector stakeholders. Dr. Urban also has extensive experience conducting both screening-level and
complex site-specific risk assessments and has developed a comprehensive knowledge base on a variety of of
regulatory guidance documents on human health risk assessment. This experience has also facilitated work with
regulatory agencies and potentially responsible parties on developing site cleanup standards. Additionally, Dr.
Urban has experience in the drug development and food safety sectors, providing oversight for GLP and non-GLP
studies in support of the FDA’s pre-IND application process for biological pharmaceuticals and conducting GRAS
reviews for food additives, respectively.
Dr. Urban is a Diplomate of the American Board of Toxicology, has published academic and professional studies in
the peer-reviewed literature, and is a reviewer for various scientific journals. While earning his Ph.D. in toxicology at
the University of North Carolina at Chapel Hill, Dr. Urban served as an enlisted communications specialist in the
United States Marine Corps Reserves (Communications Company, Greensboro, NC).

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                        1

EDUCATION AND DEGREES EARNED

Ph.D., Toxicology, University of North Carolina at Chapel Hill, 2006
B.S., Biological Sciences, University of Maryland at College Park, 1999

PROFESSIONAL ASSOCIATIONS AND AWARDS

Diplomate of the American Board of Toxicology (since 2013; recertified 2018)
Society of Toxicology (since 2004): 2006 Graduate Student Travel Award
Risk Assessment Specialty Section, SOT (since 2008)
American College of Toxicology (2012-2014)
Society of Environmental Toxicology and Chemistry (2011)
Society for Neurosciences (student member 2003–2005)

PROFESSIONAL ACTIVITIES

2013         Co-chaired SOT Continuing Education Course: Approval of Biosimilar Monoclonal Antibodies:
             Scientific, Regulatory and Legal Challenges (AM04)
2016–2017 Scientific Review Panel (Invited Guest): National Library of Medicine’s Hazardous Substances Data
          Bank. Meetings #97 (September 22–24, 2016) and #98 (January 12–14, 2017)
2017–2020 Scientific Review Panel (Permanent Member): National Library of Medicine’s Hazardous Substances
          Data Bank.
2019         Editorial board member: Toxicology Reports

SELECTED PEER REVIEW

[Web of Science ResearcherID: I-5896-2019]
Environmental Toxicity and Chemistry
Toxicological Sciences
Food and Chemical Toxicology
Regulatory Toxicology and Pharmacology
Environment International
Environmental Science and Technology
Human and Experimental Toxicology
Molecular Pharmacology
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
Neuropsychopharmacology
Toxicology Reports
Journal of Food Biochemistry
Journal of Pharmacological and Experimental Therapeutics

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                               2

SELECTED PROJECT EXPERIENCE

Sy s t emat ic Review and Evide nc ed B as ed To xic o lo gy
Applied systematic review concepts of internal, external and construct validity to a comprehensive evaluation of
the in vitro literature reporting relative potency (REP) values for dioxin-like PCBs using various human cell models
and AhR pathway endpoints. Following a weight-of-the-evidence integration and decision framework, this effort
resulted in the application of a study relevance/quality weighting scheme to the updated REP database for PCB126
to inform an updated TEF for the DL-PCB congener.
Developed a comparative assessment of in vitro critical appraisal tools (ToxRTool, SciRAP, EPA-OPPT’s TSCA
tool) using published datasets generated from human and animal cell models in support of risk evaluation related
to in utero exposures to trichloroethylene.
Conducted a risk-of-bias (RoB) assessment per the NTP-OHAT guidelines on the animal and human peer-
reviewed studies that make up the database for the hypothesis that in utero exposure to TCE causes congenital
heart defects.
Conducted systematic review of the relationship between sperm quality and pre- and perinatal dioxin exposures in
human and animal studies. Utilized the NTP’s Office of Health Assessment and Translation (OHAT) Risk of Bias
Tool to evaluate epidemiology and in vivo studies. The resulting animal evidence base was integrated into a
weighted, meta-regression analysis to characterize the dose-response relationship in rats.
Participated in evaluation for the improvement of the SciRAP in vitro critical appraisal tool, the product of a
collaboration between the researchers at Stockholm University (Department of Environmental Science and
Analytical Chemistry) and the Karolinska Institutet (Institute of Environmental Medicine).
Evaluated a systematic critical appraisal tool developed by the Department of Defense for evaluating non-cancer in
vivo datasets in support of the development of an occupational exposure level (OEL). The appraisal system
developed by the DoD is a fit-for-purpose approach that integrates elements of several available critical appraisal
tools and is currently under NAS review.
Participated in systematic review effort for the update of caffeine risk assessment evaluating consumption levels
associated with adverse effects in humans. Helped develop several endpoint-specific systematic review protocols,
and developed and applied DistillerSR screening forms for populating evidence base for endpoints of concern.
Utilized the NTP’s Office of Health Assessment and Translation (OHAT) Risk of Bias Tool to evaluate epidemiology
(experimental and observational) studies.

To xic o lo gy and Ris k A s s ess ment
Managed the evaluation of industrial hydrogen cyanide emissions in support of a state air permitting amendment.
This project involved a comprehensive assessment of the occupational and toxicology peer-reviewed and gray
literature, evaluation of federal and state monitoring and modeling tools (e.g., NATA, RSEI), coordination and
drafting of an extensive summary report, and communicated toxicology and risk information to area residents at a
public meeting coordinated by state regulatory agency.
Investigated the proposed use of USEPA TCE RfC as a short-term/immediate remediation action level; reviewed
animal toxicology, epidemiology, and toxicokinetic data on reproductive and developmental effects of TCE,
specifically as it related to fetal cardiac malformations. Worked with a state agency to develop a health hazard-
based and scientifically defensible level of concern for residential TCE exposures via vapor intrusion.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                     3

Provided toxicology support on a project in which regulatory modeled TCE air emission estimates associated with a
facility’s permitted TCE use raised concerns that potential residential exposures exceeded low level health-based
air standards developed by the state regulatory agency.
Analyzed toxicogenomics data from an in vivo bioassay that incorporated comprehensive dose-response study
design to derive estimates of relative potency (REPs) for dioxin-like compounds, comparing these early-stage
genomics-based REPs with those that had been reported using later stage endpoints (e.g., protein activity,
pathological events, etc.).
Composed a state-of-the-science toxicology report in support of updating an outdated but commonly utilized
reference dose (RfD) for copper based on chronic exposure scenarios. Critical human and animal studies were
identified from a comprehensive review of the literature and used to develop an updated RfD. The report was
submitted to a state environmental regulatory agency, and the recommendations made in this report led the
agency to update the toxicity value they used to develop their risk-based environmental copper limits (e.g., Cu-
contaminated soils).
In a project involving legacy antimony (Sb) smelter operations, performed extensive research on the toxicology and
bioavailability of various forms of antimony, the results of which were submitted to a state environmental regulatory
agency in the form of state-of-the-science reports. The recommendations made in these reports led the state
regulatory agency to update the toxicity values they used to develop their risk-based environmental antimony limits
(e.g., Sb-contaminated soils).
Evaluated the potential impact of toxicological effects in rodents observed in NTP’s 2016 antimony trioxide (Sb 2O3)
inhalation bioassay report on state soil cleanup level using preliminary benchmark dose (BMD) analytical estimates
of non-cancer and cancer endpoint potencies.
Project manager for the evaluation of perfluoronanonoic acid (PFNA), 1,4-dioxane, and 1-methylnaphthalene
toxicology in support of an effort to provide a state regulatory agency with state-of-the-science alternatives for
deriving toxicity values to serve as the basis for establishing water criteria.
Conducted and published a comprehensive human health hazard and cancer risk assessment on the ingestion of
fish sampled from the Lower Passaic River. This evaluation was comprised more than 150 chemicals of potential
concern, including PCDD/Fs, PCBs, metals, and several other organic compounds, and utilized peer-reviewed
site-specific exposure and consumption data to reduce assessment uncertainty.
Managed and conducted an analytical assessment of PCNs, PCDD/Fs, and dioxin-like PCBs in based on sediment
sampling for a prominent harbor water body in the Northeast United States. Used preliminary TCDD-based toxic
equivalency factors (TEFs) for PCN congeners to characterize PCN contribution to overall sample TEQs. Employed
PCA fingerprinting analyses to compare PCN congener profiles between sediment and technical mixtures in an
effort to identify potential PCN sources.
Provided toxicological expertise in a comprehensive analysis of impacts to an urban area in North Texas from shale
gas drilling and production.
Conducted comprehensive literature reviews on the human health effects of multiple nickel and lead compounds in
support of the European Union’s Registration, Evaluation & Authorisation of Chemicals (REACH) initiative, and
populated the International Uniform Chemical Information Database (IUCLID) substance with relevant substance-
specific data. Evaluated key studies for reliability and relevance, synthesized large volumes of data, and generated
integrative reports.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                      4

F o o d and Co ns um er Pro duc t s
Provided support as a contract toxicologist for a large consumer products business conducting screening level and
comprehensive safety assessments (when warranted) on the constituents of a variety of grooming and beauty care
products.
In support of multiple businesses, was the lead consulting toxicologist in the development of product-level safety
assessments for a series of nutrition products. This role involved review of draft product constituent assessments,
and their integration into higher level assessments on the complete products for establishing consumer use
recommendations.
Coordinated and managed subcontractor services providing toxicological guidance and expertise in support of an
initiative by FDA’s Center for Tobacco Products to develop risk assessments on unregulated tobacco products
(e.g., electronic cigarettes). Comprehensive reviews of the peer-reviewed literature were conducted and distilled
into summary documents for various tobacco-related chemicals (nicotine, tobacco-specific nitrosamines NNN and
NNK, acrolein) and numerous tobacco product ingredients (flavor additive and enhancer compounds, and
complex essential oils). In addition, we provided the client with dose-response modeling results on relevant studies
of NNK carcinogenicity, and guidance on how to present such data in exposure-response arrays.
Provided an internal assessment for a client on the potential human health risk associated with dermal exposures
to an essential oil-based residential insecticide product, using QRA models published by the Research Institute for
Fragrance Materials (RIFM) as well as the USEPA’s residential pesticide exposure model.
Managed the development of No Significant Risk Levels (NSRLs) for beta-myrcene based on the 2010 NTP
bioassay report according to Proposition 65 regulatory guidance set forth by California’s Office of Environmental
Health Hazard Assessment (OEHHA).
Managed the development of an indoor air quality model toolkit for quantifying exposure and human health risk
associated with trace volatile organic compounds present in the propellants used in consumer aerosols.
Researched and developed the safety sections of GRAS reports submitted to the U.S. Food and Drug
Administration on non-caloric sweetener products.
Researched and published review manuscripts on the potential genotoxic and allergenic hazards related to
consumption of highly purified, non-caloric sweetener products.
Served as an expert panel member for the GRAS evaluation of a high purity, non-caloric general-purpose
sweetener.
Researched and drafted comments on the carcinogenicity or developmental/reproductive toxicity of pyrethroids
(type 1 as a group and deltamethrin, respectively) for consideration by OEHHA Proposition 65 expert panels
(DARTIC and CIC, respectively).
Conducted comprehensive investigation into the mechanistic and empirical evidence supporting a potential
association between certain food preservatives (sodium benzoate, parabens) with neurodegenerative disease.
Developed risk-based toxicity values for acrylamide based on extensive review of the literature and National
Toxicology Program’s cancer bioassay data.
Provided toxicology analysis for a human health risk assessment related to a detergent contaminant (nonylphenol
ethoxylate) found at low levels in a product marketed for consumption. Integral to this assessment was the
identification of a toxicological effects level used to develop a health benchmark and the calculation of exposure
estimates, key determinants in decisions related to product shelf retention.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                      5

P harm ac eut ic als and Drug Develo pment
Visited the campuses of several different CROs to conduct site monitoring of pre-clinical toxicology studies,
including the dosing, handling and care of non-human primates, rabbits, and rodents. These were performed in
support of investigational new drug (IND) application efforts for biological drug development. Responsibilities
included evaluating CRO staff knowledge and adherence to proscribed treatment protocols, as well as general
observations on laboratory conditions and laboratory feedback from regulatory agency inspections.
Provided toxicology and pharmacology expertise in support of a pre-IND application for a novel vaccine. Involved
interpreting toxicology and pharmacology study data and facilitating sponsor and laboratory communication on
study results and future study design.
Researched and developed a comprehensive summary of the toxicology data on an over-the-counter antihistamine
pharmaceutical being considered for inclusion in a novel therapeutic formulation.
Conducted toxicological evaluations of chemical substances present or potentially present in vaccines, as well as
derived safe levels for excipients, detergents, surfactants, and other chemicals utilized in the production or
inactivation of vaccine products.
Designed and performed in vitro assays to evaluate the diverse G-protein coupled receptor-based binding and
signaling profiles of several dopaminergic ligands, with a focus on atypical antipsychotic drugs and non-clinical
development of novel Parkinson’s Disease pharmacotherapies.

O c c upat io nal H ealt h
Coordinated and provided technical support for the development of strategies to reduce worker exposure to
chemicals of potential concern at a primary magnesium production facility. Evaluated industrial hygiene and
biomonitoring data for dioxin-like compounds and hexachlorobenzene relative to the general population,
determining whether the measured levels posed a threat to worker health, and coordinated with a certified
industrial hygienist to develop recommendations on improving occupational protocols and procedures.
Developed historical exposure reconstruction analysis of coke-oven workers exposed to the benzene-soluble
fraction of total particulate matter present in coke-oven emissions. Exposure estimates were derived from
regulatory and industrial personal and area monitoring efforts for each specific coke-oven job and were used to
develop cumulative exposure and cancer risk estimates.
Conducted an extensive review of the reproductive and developmental toxicology and epidemiology literature of
glycol ethers and their respective acetates identified in more than 100 products that represented potential
exposure hazards to semiconductor facility employees. Occupational exposure was evaluated using historical
industrial hygiene data, product purchasing data, and thousands of material safety data sheets (MSDSs). Hazard
was assessed by comparing estimated exposures with toxicity criteria and regulatory exposure guidelines.
Performed a comprehensive toxicological review of various chemicals (VOCs, semi-volatile compounds, metals)
identified in various industrial products and processes to which employees of a laminated plastics plant had
potentially been exposed. In addition, employee symptoms and health complaints were compared with the
toxicological profiles of each chemical of potential concern to focus the subsequent exposure assessment.
Assisted in biomonitoring analysis focused on exposures of former and current employees to dioxins and metals at
copper smelter facilities. This work involved data analyses and interpretation regarding the levels of dioxin-like
compounds in blood samples, the results of which were compared with the levels reported in other regional and
national biomonitoring efforts to assess relative body burden.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                     6

PUBLICATIONS

Wikoff DS, Urban JD, Ring C, Britt J, Fitch S, Budinsky R, Haws LC. 2021. Development of a range of plausible
non-cancer toxicity values for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) based on effects on sperm count:
Application of systematic review methods and quantitative integration of dose response using metaregression.
Toxicol Sci 179(2): 162-182.
Urban JD, Wikoff DS, Chappell GA, Harris C, Haws LC. 2020. Systematic Evaluation of Mechanistic Data in
Assessing In Utero Exposures to Trichloroethylene and Development of Congenital Heart Defects. Toxicol
436:152427. doi:10.1016/j.tox.2020.152427.
Wikoff D, Urban JD, Harvey S, Haws LC. 2018. Role of risk of bias in systematic review for chemical risk
assessment: A case study in understanding the relationship between congenital heart defects and exposures to
trichloroethylene. Int J Toxicol 37(2):125–143.
Wikoff D, Welsh BT, Henderson R, Brorby GP, Britt J, Myers E, Goldberger J, Lieberman HR, O’Brien C, Peck J,
Tenebein M, Weaver C, Harvey S, Urban J, Doepker C. 2017. Systematic review of the potential adverse effects of
caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol
109(Pt1):585–648.
Urban JD, Carakostas MC, Taylor SL. 2015. Steviol glycoside safety: Are highly purified steviol glycoside
sweeteners food allergens? Food Chem Toxicol 75:71–78.
Bunch AG, Perry CS, Abraham L, Wikoff DS, Tachovsky JA, Hixon JG, Urban JD, Harris MA, Haws LC. 2014.
Evaluation of impact of shale gas operations in the Barnett Shale region on volatile organic compounds in air and
potential human health risks. Sci Tot Environ 468–469:832–842.
Urban JD, Wikoff DS, Bunch AT, Harris MA, Haws LC. 2014. A review of background dioxin concentrations in
urban/suburban and rural soils across the United States: Implications for site assessments and the establishment
of soil cleanup levels. Sci Tot Environ 446–467:586–597.
Rowlands JC, Budinsky R, Gollapudi B, Black M, Wolfinger R, Cukovic D, Dombkowski A, Thompson C, Urban JD,
Thomas R. 2013. A genomics-based analysis of relative potencies of dioxin-like compounds in primary rat
hepatocytes. Toxicol Sci 136(2):595–604.
Urban JD, Carakostas MC, Brusick, DJ. 2013. Steviol glycoside safety: Is the genotoxicity database sufficient?
Food Chem Toxicol 51:386–390.
Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB. 2012. Receptor conformations involved in
dopamine D2L receptor functional selectivity induced by selected transmembrane 5 serine mutations. Mol
Pharmacol 81(6):820–831.
Thompson CM, Hixon JG, Proctor DM, Haws LC, Suh M, Urban JD, Harris MA. 2012. Assessment of genotoxic
potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic
carcinogens across tissues. Regul Toxicol Pharmacol 64(1):68–76.
Urban JD, Budinsky RA, Rowlands JC. 2012. An evaluation of single nucleotide polymorphisms in the human heat
shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278.
Rowlands JC, Urban JD, Wikoff DS, Budinsky RA. 2011. An evaluation of single nucleotide polymorphisms in the
human aryl hydrocarbon receptor-interacting protein (AIP) gene. Drug Metab Pharmacokinet 26(4):431–439.
Tichomirowa MA, Bariler A, Daly AF, Jaffrain-Rea M-L, Ronchi CL, Yaneva M, Urban JD, Petrossians P, Elenkova
AP, Tabarin A, Desailloud R, Maiter D, Schürrmeyer T, Cozzi R, Theodoropoulou M, Sievers C, Bernabeu I, Naves

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                     7

LA, Chabre O, Fajardo Montañana C, Hana V, Halaby G, Delemer B, Labarta JI, Sonnet E, Ferrandez A,
Hagelstein MTs, Caron P, Stalla GK, Bours V, Zacharieva S, Spada A, Brue T, Beckers A. 2011. High prevalence
of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J
Endocrinol 165(4):509–515.
Urban JD, Rowlands JC, Budinsky RA. 2011. Single nucleotide polymorphisms in the human aryl hydrocarbon
receptor nuclear translocator (ARNT) gene. Drug Metab Pharmacokinet 26(6):637–645.
Tachovsky JA, Urban JD, Wikoff DS, Haws LC, Harris MA. 2010. Reduction of a large fish tissue analyte database:
Identifying and assessing data specific to a remediation site for risk assessment application. Chemosphere
80(5):481–488.
Urban J, Tachovsky JA, Haws L, Wikoff Staskal D, Harris M. 2010. Response to Mugdan et al.’s comment on
Urban et al., “Assessment of Human Health Risks Posed by Consumption of Fish from the Lower Passaic River,
New Jersey.” Sci Tot Environ 408(6):1468–1470.
Urban JD, Tachovsky JA, Haws LC, Staskal DF, Harris MA. 2010. Response to Buchanan et al.’s comment on
Urban et al., “Assessment of Human Health Risks Posed by Consumption of Fish from the Lower Passaic River,
New Jersey.” Sci Tot Environ 408(8):2004–2007.
Urban JD, Tachovsky JA, Staskal DF, Haws LC, Harris MA. 2009. Assessment of human health risks posed by
consumption of fish from the Lower Passaic River, New Jersey. Sci Tot Environ 408(2):209–24.
Scott LLF, Staskal DF, Haws LC, Luksemburg WJ, Birnbaum LS, Urban JD, Williams ES, Nguyen LM, Paustenbach
DJ, Harris MA. 2009. Levels of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls in southern
Mississippi catfish and estimation of potential health risks. Chemosphere 74(7):1002–1010.
Staskal DF, Scott LLF, Birnbaum LS, Williams ES, Haws LC, Luksemburg WJ, Urban JD, Nguyen LM, Paustenbach
DJ, Harris MA. 2008. Polybrominated diphenyl ethers in farm-raised and wild-caught catfish from southern
Mississippi. Environ Sci Technol 42(17):6755–6761.
Urban JD, Clarke WP, von Zastrow M, Kobilka B, Nichols DE, Weinstein H, Javitch JA, Roth BL, Christopoulos A,
Sexton PM, Miller KJ, Spedding M, Mailman RB. 2007. Functional selectivity and classical concepts of quantitative
pharmacology (Perspective in Pharmacology). J Pharmacol Experimental Therapeut 320(1):1–13 [Journal Cover].
Urban JD, Vargas G, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at D2
receptor-mediated signaling pathways. Neuropsychopharmacol 32(1):67–77.
Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. 2004. Functional selectivity of D2 receptor ligands in a
Chinese hamster ovary hD2L cell line: Evidence for induction of ligand-specific receptor states. Molec Pharmacol
66(1):97–105.

PROTOCOLS

Urban J, Wikoff D, Haws L, Fitch S, Ring C, Thompson C, Suh M. 2018. Systematic review protocol: Systematic
review and meta-regression to characterize the dose-response relationship between exposure to dioxin-like
compounds during sensitive windows of development and reduced sperm count. Zenodo.
http://doi.org/10.5281/zenodo.1636357.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                    8

Wikoff D, Doepker C, Welsh B, Urban J, Henderson R, Brorby G, Britt J, Harvey S, Goldberger J, Myers E, O'Brien
C, Peck J, Lieberman H, Weaver C, Tenebein M. 2015. Systematic review of the adverse cardiovascular effects of
caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO
2015:CRD42015026673. Available from
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026673
Wikoff D, Doepker C, Welsh B, Urban J, Henderson R, Britt J, Harvey S, Goldberger J, Myers E, O’Brien C, Peck J,
Lieberman H, Weaver C, Tenebein M. 2015. Systematic review of the adverse bone and calcium balance effects of
caffeine consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO
2015:CRD42015026609 Available from
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026609
Wikoff D, Doepker C, Welsh B, Harvey S, Goldberger J, Lieberman H, Myers E, O’Brien C, Peck J, Tenebein M,
Urban J, Weaver C. 2015. Systematic review of the adverse reproductive and developmental effects of caffeine
consumption in healthy adults, pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026736
Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026736
Wikoff D, Doepker C, Welsh B, Harvey S, Goldberger J, Lieberman H, Myers E, O’Brien C, Peck J, Tenebein M,
Urban J, Weaver C. 2015. Systematic review of acute adverse effects of caffeine consumption in healthy adults,
pregnant women, adolescents, and children. PROSPERO 2015:CRD42015026704 Available from
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015026704

INVITED LECTURES AND PRESENTATIONS

Urban, J.D., K. Burkhalter, J.A. Tachovsky, C. Thompson, L.C. Haws, and M.A. Harris. 2010. Evaluation of
Polychlorinated Naphthalenes (PCNs) in Newark Bay Sediment. Presented during the Dioxin-Like Compounds in
Urban Waterbodies Session at the 30th International Symposium on Halogenated Persistent Organic Pollutants.
September 14, 2010. San Antonio, Texas.
Urban, J.D. and R.B. Mailman. 2005. Functional selectivity as a mechanism of action for newer atypical
antipsychotic drugs. Presented at: Merck, West Point, Pennsylvania.

ABSTRACTS AND PRESENTATIONS

Urban JD, Wikoff DS, Chappell GA, Haws LC. 2020. A systematic evaluation of the mechanistic data relevant to in
utero exposures to trichloroethylene and the development of congenital heart defects. Presented at the Society of
Risk Analysis 2020 Annual Meeting. December 13-17, 2020. Virtual Meeting.
Urban JD, Wikoff DS, Fitch S, Ring CL, Haws LC, Harris MA. 2019. An assessment of the relative potency of the
dioxin-like polychlorinated biphenyl PCB126: Are the human in vitro studies sufficient? Presented at the 39th
International Symposium on Halogenated Persistent Organic Pollutants. August 25-30, 2019. Kyoto, Japan.
Urban JD, Wikoff DS, Fitch S, Ring CL, Haws LC, Harris MA. 2019. An Evaluation of the Utility of Human Cell
Models for Characterizing Relative Potency for Dioxin-like Compounds. Presented at the IUTOX 15th International
Congress of Toxicology (ICTXV). July 15-18, 2019. Honolulu, HI. Abstract #0948.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                   9

Urban JD, Wikoff DS, Haws LC. 2019. Three-tiered approach to integrating evidence streams assessing
gestational trichloroethylene exposure and congenital heart defects (TCE-CHD). Presented at the National
Academy of Sciences, Engineering and Medicine Workshop: Evidence Integration in Chemical Assessments:
Challenges Faced in Developing and Communicating Human Health Effect Conclusions. June 3-4, 2019.
Washington DC.
Urban JD, Wikoff D, Suh M, Britt J, Fitch S, Chappell G, Haws LC. 2019. Comparison of NTP OHAT and USEPA
TSCA Study Quality Criteria - Trichloroethylene (TCE) and Congenital Heart Defects (CHDs) as a Case Study.
Presented at the 58th Annual Meeting of Society of Toxicology. March 10-14, 2019. Baltimore, MD. Abstract
#2801-P305.
Ring CL, Urban JD, Wikoff D, Thompson CM, Budinsky RA, Haws LC. 2019. Application of Systematic Review and
Quantitative Evidence Integration Methods to Support Risk Assessment: Characterization of the Dose-Response
Relationship between Exposure to Dioxin-Like Compounds (DLC) and Sperm Count. Presented at the 58th Annual
Meeting of Society of Toxicology. March 10-14, 2019. Baltimore, MD. Abstract #3492-P288.
Wikoff D, Urban J, Chappell G, Haws LC. 2018. Application of Mechanistic Data Quality Criteria in Assessment of
the Relationship Between Congenital Heart Defects and TCE Exposure – A Case Study. Presented at the National
Academy of Sciences, Engineering and Medicine Workshop: Strategies and Tools for Conducting Systematic
Reviews of Mechanistic Data to Support Chemical Assessments. December 10-11, 2018. Washington DC.
Wikoff D, Ring CL, Thompson C, Urban J, Budinsky RA, Haws LC. 2018. Characterization of the dose-response
relationship for TCDD and changes in sperm concentration in rats using meta-regression: A feasibility assessment
of quantitative evidence integration techniques. Presented at the 38th International Symposium on Halogenated
Persistent Organic Pollutants. August 26-31, 2018. Krakow, Poland.
Urban JD, Harvey S, Wikoff D, Haws LC. 2018. Assessment of Study Quality (Risk of Bias) in Understanding the
Relationship Between Congenital Heart Defects (CHDs) and Exposures to Trichloroethylene (TCE). Presented at
the 57th Annual Meeting of Society of Toxicology. March 11-15, 2018. San Antonio, TX. Abstract # 2842-P365.
Borghoff SJ, Wikoff D, Urban JD, Rager JE. 2018. A Systematic Approach to Identify Plausible Mode-of-Actions
(MOAs) for an Increased Incidence of Lung Tumors in Mice with Chronic Exposure to 4-Methylimidazole (4-MEI).
Presented at the 57th Annual Meeting of Society of Toxicology. March 11-15, 2018. San Antonio, TX.
Urban JD, Thompson CM, Plunkett LM, Perry CS, Haws LC. 2015. A state of the science copper reference dose
for soil remediation. Presented at the Society of Toxicology’s 54th Annual Meeting, March 22–26, 2015. San
Diego, CA.
Urban JD, Perry C, Wikoff D, Abraham L, Harris MA. 2015. Lower Passaic River RM0-8: An alternative human
health risk assessment. Presented at the 8th International Conference on Remediation and Management of
Contaminated Sediments. January 12-15, 2015. New Orleans, LA. Abstract # 272.
Abraham L, Harris MA, Perry C, Urban JD, Wikoff D, Kinnell JC, Bingham M, Hickman S. 2015. Lower Passaic
River RM0-8: An alternative preliminary remediation goal. Presented at the 8th International Conference on
Remediation and Management of Contaminated Sediments. January 12-15, 2015. New Orleans, LA. Abstract #
187.
Urban JD, Doepker CL, Cuellar-Kingston N, van de Ligt J, Carakostas M. 2013. Do highly purified steviol glycoside
sweeteners cause food allergies? Presented at the Society of Toxicology’s 53rd Annual Meeting, March 23–27,
2014. Phoenix, AZ.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                               10

Urban JD, Thompson CM, Deskin R, Waite M, Haws LC. 2013. Development of an oral cancer slope factor for
acrylamide based on tumors relevant to humans. Presented at the 52nd Annual Meeting of Society of Toxicology.
March 10–14, 2013. San Antonio, TX. Abstract #2221-419.
Urban J, Rowlands JC, Budinsky R, Dombkowski A, Thompson CM, Thomas R. 2012. A genomics-based
benchmark dose analyses of relative potencies of dioxin like compounds in primary rat hepatocytes. Presented at
the 51st Annual Meeting of Society of Toxicology. March 11–15, 2012. San Francisco, CA. Abstract # 1726. [Top
10 abstract in SOT Risk Assessment Specialty Section.]
Perry C, Tachovsky JA, Ke M, Urban J, Haws L. 2012. Natural gas exploration and production in the Barnett
Shale: Assessment of exposures to volatile organic compounds (VOCs). Presented at the 51st Annual Meeting of
Society of Toxicology. March 11–15, 2012. San Francisco, CA. Abstract # 108.
Rowlands JC, Budinsky R, Gollapudi B, Cukovic D, Salagrama S, Dombkowski A, Urban J, Thompson C, Thomas
R. 2011. An evaluation of relative changes in genomic gene expression in primary rat hepatocytes exposed to
TCDD, 4-PeCDF, and TCDF. Presented at the 31st International Symposium on Halogenated Persistent Organic
Pollutants. August 21–25, 2011. Brussels, Belgium.
Rowlands JC, Urban J, Wikoff DS, Budinsky R. The presence and estimated functional effect of single nucleotide
polymorphisms at the AIP, ARNT, HSP90AA1, and HSP90AB1 loci in the human population. Presented at the 31st
International Symposium on Halogenated Persistent Organic Pollutants, August 21–25, 2011. Brussels, Belgium.
Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD, Dombkowski A. Genomic approaches for
relative potency assessment. Presented at the 31st International Symposium on Halogenated Persistent Organic
Pollutants. August 21–25, 2011. Brussels, Belgium.
Budinsky R, Urban J, Rowlands JC. An evaluation of single nucleotide polymorphisms in the human aryl
hydrocarbon receptor nuclear translocator gene. Presented at the Society of Toxicology’s 50th Annual Meeting,
March 6–10, 2011. Washington, D.C.
Fitzgerald L, Burkhalter B, Urban J, Staskal D, Harris M, Haws L. VOC serum levels in the general U.S. population:
An analysis of the 2003-2004 NHANES dataset. Presented at the Society of Toxicology’s 50th Annual Meeting,
March 6–10, 2011. Washington, D.C.
Urban J, Fitzgerald L, Burkhalter B, Staskal D, Harris M, Haws L. BTEX serum levels in the general U.S.
population: An analysis of 2003-2004 NHANES dataset. Presented at the Society of Toxicology’s 50th Annual
Meeting, March 6–10, 2011. Washington, D.C.
Haws L, Tachovsky JA, Staskal-Wikoff D, Aylward L, Burkhalter B, Urban J, Simon T, Harris M. 2010. An
evaluation of the influence of different soil cleanup levels on the concentration of dioxin-like compounds in human
serum. Presented at the 30th International Symposium on Halogenated Persistent Organic Pollutants. September
12–17, 2010. San Antonio, TX.
Urban J, Burkhalter B, Tachovsky JA, Haws L, Harris M. Evaluation of polychlorinated naphthalenes (PCNs) in
Newark Bay sediment. Presented at the 30th International Symposium on Halogenated Persistent Organic
Pollutants. September 12–17, 2010. San Antonio, TX.
Harris M, Tachovsky JA, Staskal-Wikoff D, Simon T, Burkhalter B, Urban J, Haws L. Assessment of the impact of
various soil cleanup levels on serum concentrations of dioxin-like compounds in humans. Presented at the 49th
Annual Meeting of Society of Toxicology. March 7–11, 2010. Salt Lake City, Utah.
Tachovsky A, Staskal D, Urban J, Harris MA, Haws L. Assessment of environmental data collected in a community
with numerous petroleum refining and petrochemical facilities. Presented at the 49th Annual Meeting of Society of
Toxicology. March 7–11, 2010. Salt Lake City, Utah.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                   11

Urban JD, Tachovsky JA, Staskal DF, Haws LC, Harris MA. Human health risk assessment of consumption of fish
from the Lower Passaic River. Presented at the 48th Annual Meeting of Society for Toxicology. March 15–19,
2009. Baltimore, MD.
Urban JD, Haws LC, Staskal DF, Scott LF, Scott PS, Tachovsky AT, Unice KM, Harris MA. 2008. A framework for
evaluating serum dioxin data derived from biomonitoring studies. Presented at the 28th International Symposium
on Halogenated Persistent Organic Pollutants. August 17–22, 2008. Birmingham, England.
Urban JD, Haws LC, Scott LF, Scott PS, Staskal DF, Tachovsky AT, Unice KM, Harris MA. 2008. A framework for
evaluating serum dioxin data derived from biomonitoring studies. Presented at the 47th Annual Meeting of Society
for Toxicology. March 16–20, 2008. Seattle, WA. Abstract # 1198–637.
Urban JD, Thornley K, Wightman RW, Mailman RB. Pharmacological characterization of the N27-D2L cell line:
Assessment as a viable cell model for investigating D2L receptor dopaminergic-coupled functions. Presented at
the 46th Annual Meeting of Society for Toxicology. March 25–29, 2007. Charlotte, NC. Abstract # 1058–231.
Fuhrmann K, Urban J, Mailman R. 2006. TM5 serines effect on D2L dopamine receptor partial agonist
pharmacology: Elucidating functional selectivity. Presented for the 2006 Summer Undergraduate Research
Experience, University of North Carolina, Chapel Hill, NC. July 26, 2006.
Urban JD, Jin J, Mailman RB. 2006. N27 dopaminergic cell line: A useful model for studying the mechanisms of
action of functionally selective dopaminergic compounds. Presented at the 45 th Annual Meeting of Society for
Toxicology. March 5–9, 2006. San Diego, CA. Abstract # 1374.
Urban JD, Mailman RB. Characterization of the N27 dopaminergic cell line as a model for elucidating the actions of
functionally selective dopaminergic ligands. Presented at the 35th Annual Neuroscience Meeting. November 12–
16, 2005. Washington, DC. Abstract # 32.21.
Urban JD, Mailman RB. 2005. Functional selectivity as a mechanism of action for newer atypical antipsychotic
drugs. Presented at: Merck, West Point, Pennsylvania, USA.
Urban JD, Gay, Mailman RB. Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs.
Presented at the 34th Annual Neuroscience Meeting. October 23–27, 2004. San Diego, CA. Abstract # 163.4.
Urban JD, Gay EA, Mailman RB. 2004. Decreased neurological side-effects with aripiprazole: A result of functional
selectivity of the D2 receptor? Presented at the 43rd Annual Meeting of Society for Toxicology. March 21–25, 2004.
Baltimore, MD. Abstract # 313.

SELECTED CONTINUING EDUCATION

Embryology and Developmental Toxicity Testing. Society of Toxicology. March 13, 2016.
Human Health Risk Assessment: A Case Study Application of Principles. Society of Toxicology. March 13, 2016.
Adverse Outcome Pathway (AOP) Development and Evaluation. Society of Toxicology. March 13, 2016.
Gonadal Development, Function, and Toxicology. Society of Toxicology. March 10, 2013.
Approval of Biosimilar Monoclonal Antibodies: Scientific, Regulatory and Legal Challenges. Society of Toxicology.
March 10, 2013.
Best Practices for Developing, Characterizing, and Applying Physiologically Based Pharmacokinetic Models in Risk
Assessment. Society of Toxicology. March 6, 2011.

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                                 12

Beyond Science and Decisions: From Problem Formulation to Dose-Response. Workshop I. Alliance for Risk
Assessment. March 16-18, 2010.
Epidemiology for Toxicologists: Introduction. Society of Toxicology. March 16, 2008.
Dose Response Modeling for Occupational and Environmental Risk Assessment. Society of Toxicology. March 16,
2008.
Allergy and Allergic Disease: A Primer for Toxicologists. Society of Toxicology. March 25, 2007.
Neuropathology for the Toxicologist. Society of Toxicology. March 5, 2006.
Essentials of Metal Toxicology. Society of Toxicology. March 5, 2006

JONATHAN D. URBAN, PH.D., DABT | SEPTEMBER 2021                                                          13